Overview
Kisspeptin is a family of neuropeptides encoded by the KISS1 gene, with kisspeptin-54 being the full-length form and kisspeptin-10 the most commonly used truncated active fragment. Its role as the master regulator of the reproductive hormone axis was established in 2003 when loss-of-function mutations in its receptor (KISS1R/GPR54) were linked to hypogonadotropic hypogonadism.
Kisspeptin neurons in the hypothalamus serve as upstream gatekeepers of GnRH secretion. By stimulating GnRH neurons, kisspeptin controls LH, FSH, and sex steroid production. Clinical trials have demonstrated that kisspeptin can trigger oocyte maturation in IVF with significantly lower OHSS risk compared to hCG.
Research at Imperial College London has pioneered its use in reproductive medicine, while ongoing studies explore applications in hypogonadism, PCOS, functional hypothalamic amenorrhea, and psychosexual disorders.
This guide examines kisspeptin biology, clinical evidence, safety data, and its rapidly evolving therapeutic landscape.
Quick facts
- Mechanism
- Master upstream regulator of GnRH and reproductive hormone axis
- Primary use
- Fertility Medicine & Reproductive Hormone Regulation
- Evidence
- strong
- FDA
- Not approved
- Route
- Intravenous or subcutaneous injection (clinical research)
- Typical results
- Robust LH pulse induction within 30–60 minutes of IV administration
Chemical information
Kisspeptin-10 (C₆₃H₈₃N₁₇O₁₄) is a hormonal compound with a molecular weight of 1302.4 g/mol. Its structural characteristics underpin its biological activity in hormonal signaling and endocrine function.
How Kisspeptin-10 works
Kisspeptin binds KISS1R (GPR54) on hypothalamic GnRH neurons, activating Gq/11 signaling, phospholipase C, IP3-mediated calcium release, and GnRH neuron depolarization, leading to pulsatile GnRH secretion and downstream LH/FSH release.
Kisspeptin neurons integrate metabolic (leptin), circadian (melatonin), stress (cortisol), and sex steroid signals to modulate GnRH output. This makes kisspeptin neurons the central hub where diverse physiological inputs converge to regulate reproduction.
AVPV kisspeptin neurons mediate positive estrogen feedback for the pre-ovulatory LH surge, while arcuate nucleus kisspeptin neurons mediate negative feedback. This dual-population model explains both tonic and surge-mode GnRH secretion.
Beyond reproduction, kisspeptin enhances limbic brain activity in response to sexual and bonding cues in human fMRI studies, suggesting a role in psychosexual function beyond hormone regulation.
- KISS1R activation: Triggers Gq/11-PLC-IP3 calcium signaling on GnRH neurons
- GnRH pulse generation: Stimulates pulsatile GnRH release for normal gonadotropin secretion
- LH/FSH regulation: Controls downstream gonadotropin secretion
- Metabolic integration: Leptin receptor expression links energy to reproductive function
- Sex steroid feedback: Mediates both positive and negative estrogen feedback
- Limbic processing: Enhances sexual and bonding brain activity
Pharmacokinetics
| Parameter | Value | Significance |
|---|---|---|
| Bioavailability | Rapid IV/SC absorption; near 100% IV bioavailability | Kisspeptin-54 preferred clinically due to longer duration |
| Onset of Action | LH rise within 15–30 minutes of IV administration | Time to measurable clinical/biological response |
| Half-life | Kisspeptin-10: ~4 min; Kisspeptin-54: ~28 min | Determines dosing frequency |
| Duration of Effect | LH elevation persists 4–6 hours after single bolus | Functional activity beyond plasma clearance |
| Metabolism | Rapid proteolytic degradation; renal clearance | Primary elimination pathway |
Dosing & administration
Kisspeptin-10 dosing varies by indication and individual factors. No FDA-approved dosing exists for this compound; protocols in the literature derive from limited clinical or preclinical data and practitioner experience.
Any use should be conducted under qualified medical supervision with appropriate monitoring of safety markers.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Safety data for Kisspeptin-10 is primarily derived from preclinical studies and limited human data. Long-term effects in humans remain incompletely characterized.
Common
- • Facial flushing (~30%)
- • Transient warmth/tingling
- • Mild headache
- • Injection site discomfort
- • Nausea (uncommon)
- • Transient tachycardia
Serious / potential risks
- • No serious adverse events in published clinical trials
- • Theoretical premature LH surge in IVF
- • Tachyphylaxis with continuous infusion
- • Unknown chronic administration effects
- • Contraindicated in hormone-sensitive malignancies
Drug interactions
| Medication | Interaction | Recommendation |
|---|---|---|
| GnRH agonists (leuprolide) | Redundant HPG stimulation; unpredictable responses | Avoid combination or use with extreme caution under medical supervision |
| GnRH antagonists (cetrorelix) | May block kisspeptin's downstream effects at GnRH receptors | Avoid combination or use with extreme caution under medical supervision |
| Oral contraceptives | Exogenous sex steroids alter kisspeptin feedback loops | Monitor closely; dose adjustment may be required |
| Testosterone/Estrogen | Exogenous sex steroids modify kisspeptin neuron activity | Monitor closely; dose adjustment may be required |
Storage & handling
Lyophilized Powder
- • Store at -20°C long-term
- • Protect from light
- • Stable at 4°C for 4 weeks
- • Desiccant recommended
Reconstituted Solution
- • Reconstitute with sterile saline
- • Refrigerate at 2–8°C
- • Use within 14 days
- • Do not freeze
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research suppliers | Varies widely | Quality and purity vary significantly between sources |
| Compounding pharmacies | Prescription required | Higher quality assurance and purity testing |
The bottom line
Kisspeptin-10 is a hormonal compound with research interest in reproductive health, gnrh, fertility, puberty. While preclinical evidence is encouraging, it remains investigational and is not FDA-approved. Any use should be under qualified medical supervision.
Best for
- • Researchers studying hormonal signaling and endocrine function
- • Individuals interested in reproductive health under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
Frequently asked questions
References
- [1] Dhillo WS, Chaudhri OB, Patterson M, et al.. Kisspeptin-54 stimulates the HPG axis in human males. J Clin Endocrinol Metab (2005). doi: 10.1210/jc.2005-1468 PMID: 16174713
- [2] Abbara A, Jayasena CN, Christopoulos G, et al.. Kisspeptin-54 triggers oocyte maturation in women at high OHSS risk. J Clin Endocrinol Metab (2015). doi: 10.1210/jc.2015-2332 PMID: 26305622
- [3] Comninos AN, Wall MB, Demetriou L, et al.. Kisspeptin modulates sexual and emotional brain processing. J Clin Invest (2017). doi: 10.1172/JCI89519 PMID: 28002494
- [4] Seminara SB, Messager S, Chatzidaki EE, et al.. GPR54 as a regulator of puberty. N Engl J Med (2003). doi: 10.1056/NEJMoa035322 PMID: 14573733